8legs: Institute of cancer research

#1 out of 1

AI to predict how bowel cancer patients will respond to new NHS drug

AI-driven PhenMap analyzes complex tumor data to predict bevacizumab response in bowel cancer.
117 European bowel cancer patients were studied after receiving chemotherapy and bevacizumab.
Researchers aim to spare thousands from ineffective treatment and side effects.
The NHS recently approved bevacizumab for some bowel cancer patients.
Researchers say larger cohorts are needed to validate the approach before clinical use.
The study aims to develop a future test for clinicians to personalize care.
Bevacizumab slows tumor growth but benefits only some patients and has risks.
The researchers aim to expand patient samples in future work.
The study links to broader efforts in precision medicine for cancer.
Researchers see AI enabling clinicians to tailor treatments more effectively.
The Guardian reports the study was conducted in Europe and published April 2026.

Vote 0